

Oncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Iberdomide is a potent drug differentiated from classic immunomodulatory agents by which of the following?
  - a. Distinct chemical structure
  - b. Higher affinity for cereblon
  - c. More efficient substrate degradation
  - d. All of the above
  
2. The ongoing Phase III MIDAS IFM 2020-02 trial is evaluating iberdomide in combination with isatuximab versus lenalidomide in combination with isatuximab in which of the following settings?
  - a. Transplant-eligible newly diagnosed multiple myeloma (NDMM)
  - b. Transplant-ineligible NDMM
  - c. Post-autologous stem cell transplant maintenance
  - d. Lenalidomide and pomalidomide-refractory disease
  
3. Which of the following treatment-emergent adverse events led to the highest incidence of dose reduction and interruption in patients with relapsed/refractory multiple myeloma who received mezigdomide in combination with dexamethasone in early-phase clinical trials?
  - a. Anemia
  - b. Diarrhea
  - c. Fatigue
  - d. Neutropenia
  - e. Pyrexia
  
4. Which of the following proteins is targeted for degradation by modulated cereblon E3 ligase?
  - a. Aiolos
  - b. Ikaros
  - c. Both a and b
  - d. Neither a nor b
  - e. I'm not sure
  
5. Which of the following best describes the target function of the monofunctional degradation activating compound CFT7455?
  - a. BRAF-V600 degradation
  - b. BRD9 degradation
  - c. IKZF1/3 degradation
  - d. p21 degradation